Conclusion

Applicant requests examination of the claims as amended. Should there be any minor matters preventing such examination, applicant requests that the Examiner contact the attorney indicated below.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: New York, New York
February 27, 2002

By: _____
Elie H. Gendloff
Registration No.: 44,704

Appendix
Marked up amendments
Continuation of U.S. Patent Application 09/245,169, Filed February 27, 2002
Added material is underlined; deleted material is bracketed.

In the Specification:

On page 14, the paragraph on lines 7-11 has been amended as follows:

Figure 5. Figure 5 depicts the DNA sequence of a PDE1C cDNA (SEQ ID NO:1) that confirms that PDE1C is expressed in pancreatic islet ß-cells. Reverse transcriptase polymerase chain reaction was used to amplify and clone a fragment of the PDE1C mRNA common to all known PDE1C isozymes.

On page 28, the two paragraphs on lines 10-25 have been amended as follows:

--Reverse transcriptase polymerase chain reaction (RT-PCR) analysis. RT-PCR analysis was performed on 5 μg of RNA prepared from ßTC3 cells using Trizol (Gibco-BRL). Controls lacking reverse transcriptase were included in the reactions. To determine expression of PDE1C the following oligonucleotides were used: for RT - oligo dT; and for PCR amplification - JWPDE1C-5 5'-ACAGGGCAGAGGAGATCAAGTTT (SEQ ID NO:2); and JWPDE1C-3 5'-CTTTTCGCCTGCCTTTTCTCCTT (SEQ ID NO:3). The 408 bp PCR product was cloned and its DNA sequence was determined.

The following oligonucleotides were used for PCR amplification to determine the expression of PDE4A: JWPDE4A-5 5'-AGCCATGGAACAGTCAAAGGTCAA (SEQ ID NO:4); and JWPDE4A-3 5'-TCAGGAGGGCCAGGAGTCGT (SEQ ID NO:5); and to determine the expression of PDE4D: JWPDE4D-5 5'-GAGGGCCGGCAGGGACAGAC (SEQ ID NO:6); and JWPDE4D-3 5'-GGGGGTGGGGTGGGTGAGAGG (SEQ ID NO:7). Amplification products 436 AND 470 bp long were obtained for PDE4A and D, respectively.--